Cargando…

Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective

Crystalline organic nanoparticles and their amorphous equivalents (ONP) have the potential to become a next-generation formulation technology for dissolution-rate limited biopharmaceutical classification system (BCS) class IIa molecules if the following requisites are met: (i) a quantitative underst...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhlemann, Jens, Diedam, Holger, Hoheisel, Werner, Schikarski, Tobias, Peukert, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823784/
https://www.ncbi.nlm.nih.gov/pubmed/33374375
http://dx.doi.org/10.3390/pharmaceutics13010022
_version_ 1783639918581383168
author Uhlemann, Jens
Diedam, Holger
Hoheisel, Werner
Schikarski, Tobias
Peukert, Wolfgang
author_facet Uhlemann, Jens
Diedam, Holger
Hoheisel, Werner
Schikarski, Tobias
Peukert, Wolfgang
author_sort Uhlemann, Jens
collection PubMed
description Crystalline organic nanoparticles and their amorphous equivalents (ONP) have the potential to become a next-generation formulation technology for dissolution-rate limited biopharmaceutical classification system (BCS) class IIa molecules if the following requisites are met: (i) a quantitative understanding of the bioavailability enhancement benefit versus established formulation technologies and a reliable track record of successful case studies are available; (ii) efficient experimentation workflows with a minimum amount of active ingredient and a high degree of digitalization via, e.g., automation and computer-based experimentation planning are implemented; (iii) the scalability of the nanoparticle-based oral delivery formulation technology from the lab to manufacturing is ensured. Modeling and simulation approaches informed by the pharmaceutical material science paradigm can help to meet these requisites, especially if the entire value chain from formulation to oral delivery is covered. Any comprehensive digitalization of drug formulation requires combining pharmaceutical materials science with the adequate formulation and process technologies on the one hand and quantitative pharmacokinetics and drug administration dynamics in the human body on the other hand. Models for the technical realization of the drug production and the distribution of the pharmaceutical compound in the human body are coupled via the central objective, namely bioavailability. The underlying challenges can only be addressed by hierarchical approaches for property and process design. The tools for multiscale modeling of the here-considered particle processes (e.g., by coupled computational fluid dynamics, population balance models, Noyes–Whitney dissolution kinetics) and physiologically based absorption modeling are available. Significant advances are being made in enhancing the bioavailability of hydrophobic compounds by applying innovative solutions. As examples, the predictive modeling of anti-solvent precipitation is presented, and options for the model development of comminution processes are discussed.
format Online
Article
Text
id pubmed-7823784
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78237842021-01-24 Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective Uhlemann, Jens Diedam, Holger Hoheisel, Werner Schikarski, Tobias Peukert, Wolfgang Pharmaceutics Review Crystalline organic nanoparticles and their amorphous equivalents (ONP) have the potential to become a next-generation formulation technology for dissolution-rate limited biopharmaceutical classification system (BCS) class IIa molecules if the following requisites are met: (i) a quantitative understanding of the bioavailability enhancement benefit versus established formulation technologies and a reliable track record of successful case studies are available; (ii) efficient experimentation workflows with a minimum amount of active ingredient and a high degree of digitalization via, e.g., automation and computer-based experimentation planning are implemented; (iii) the scalability of the nanoparticle-based oral delivery formulation technology from the lab to manufacturing is ensured. Modeling and simulation approaches informed by the pharmaceutical material science paradigm can help to meet these requisites, especially if the entire value chain from formulation to oral delivery is covered. Any comprehensive digitalization of drug formulation requires combining pharmaceutical materials science with the adequate formulation and process technologies on the one hand and quantitative pharmacokinetics and drug administration dynamics in the human body on the other hand. Models for the technical realization of the drug production and the distribution of the pharmaceutical compound in the human body are coupled via the central objective, namely bioavailability. The underlying challenges can only be addressed by hierarchical approaches for property and process design. The tools for multiscale modeling of the here-considered particle processes (e.g., by coupled computational fluid dynamics, population balance models, Noyes–Whitney dissolution kinetics) and physiologically based absorption modeling are available. Significant advances are being made in enhancing the bioavailability of hydrophobic compounds by applying innovative solutions. As examples, the predictive modeling of anti-solvent precipitation is presented, and options for the model development of comminution processes are discussed. MDPI 2020-12-24 /pmc/articles/PMC7823784/ /pubmed/33374375 http://dx.doi.org/10.3390/pharmaceutics13010022 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Uhlemann, Jens
Diedam, Holger
Hoheisel, Werner
Schikarski, Tobias
Peukert, Wolfgang
Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
title Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
title_full Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
title_fullStr Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
title_full_unstemmed Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
title_short Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
title_sort modeling and simulation of process technology for nanoparticulate drug formulations—a particle technology perspective
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823784/
https://www.ncbi.nlm.nih.gov/pubmed/33374375
http://dx.doi.org/10.3390/pharmaceutics13010022
work_keys_str_mv AT uhlemannjens modelingandsimulationofprocesstechnologyfornanoparticulatedrugformulationsaparticletechnologyperspective
AT diedamholger modelingandsimulationofprocesstechnologyfornanoparticulatedrugformulationsaparticletechnologyperspective
AT hoheiselwerner modelingandsimulationofprocesstechnologyfornanoparticulatedrugformulationsaparticletechnologyperspective
AT schikarskitobias modelingandsimulationofprocesstechnologyfornanoparticulatedrugformulationsaparticletechnologyperspective
AT peukertwolfgang modelingandsimulationofprocesstechnologyfornanoparticulatedrugformulationsaparticletechnologyperspective